BioSpace News Archive

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported its operating and financial results for the first quarter ended March 31, 2020.

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ Provides Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Moderate Traumatic Brain Injury

Starton Therapeutics Inc. announced that it has filed PCT and US Non-Provisional patent applications entitled “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” on April 21, 2020.

FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN

KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

Zimmer Biomet Holdings, Inc. announced that President and CEO Bryan Hanson and Executive Vice President and Chief Financial Officer Suky Upadhyay will be participating in a fireside chat at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, at 10:20 a.m. Eastern Time.

Oncolytics Biotech® Inc., announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting to be held at 4:30 p.m. on May 7, 2020..

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2020 financial results on Thursday, May 7, after the close of the U.S. financial markets..

Bausch Health Companies Inc. announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2020, at 1:40 p.m. EDT..

Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.